Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Pharmaceutical company spanning APIs (historically dominant in antiretrovirals for HIV, plus oncology and other APIs), finished-dosage formulations for global tender and regulated markets, a fast-growing CDMO/synthesis business serving innovator pharma (Laurus Synthesis), and a biotechnology arm (Laurus Bio) in precision fermentation. The CDMO segment, including large multi-year contracts, has become the key growth and margin driver as legacy ARV pricing matured.
One of the world's largest manufacturers of antiretroviral APIs, now transitioning into a diversified CDMO player.
Laurus Labs Ltd. is a constituent of NIFTY 200, NIFTY 500, NIFTY HEALTHCARE, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Laurus Labs Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 16.47 | 6.65 | 2.98 |
| Book value / share (₹) | 100.61 | 85.35 | 76.36 |
| Return on equity | 16.4% | 7.8% | 3.9% |
| Return on capital employed | 18.9% | 10.8% | 7.5% |
| Operating margin | 19.1% | 11.3% | 7.8% |
| Net margin | 13.1% | 6.5% | 3.2% |
| EBITDA | ₹1,778 Cr | ₹1,055 Cr | ₹778 Cr |
| Free cash flow | ₹554 Cr | ₹-39 Cr | ₹-13 Cr |
| Total debt | ₹2,397 Cr | ₹2,693 Cr | ₹2,507 Cr |
| Debt to equity | 0.44 | 0.59 | 0.61 |
| Interest coverage | 7.6 | 2.9 | 2.1 |
| Current ratio | 1.33 | 1.22 | 1.23 |
| Shares outstanding | 53,98,50,000 | 53,92,50,000 | 53,89,50,000 |
Open the full income statement, balance sheet and cash flow for LAURUSLABS →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.